A recent structural study provided a blueprint of how CIP2A binds and inhibits B56α, which could guide the design of molecules to block CIP2A-B56 binding and free PP2A to do its tumor-suppressive work (Pavic et al., 2023). This evidence concerns the gene PTPA and neoplasm.